Managing adverse reactions to psychotropic medications

Pediatric Annals

Volumn 34, Issue 12, 2005, Pages 947-954

  Bebarta, Vikhyat S ^a,b,c,g   Kostic, Mark A ^d,e,f   Gonzales, Michael G ^a,c  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c USAF Medical Corps   (United States)

^d NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^f Space and Naval Warfare Systems Center Pacific   (United States)

^g Wilford Hall USAF Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHETAMINE DERIVATIVE; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DROPERIDOL; HALOPERIDOL; METHYLPHENIDATE; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; ZIPRASIDONE;

ADOLESCENT; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTICHOLINERGIC EFFECT; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BRAIN DISEASE; BRAIN EDEMA; CATARACT; CENTRAL NERVOUS SYSTEM DEPRESSION; CHILD; CONSTIPATION; DIABETES MELLITUS; DIZZINESS; DRUG ABUSE; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FANCONI RENOTUBULAR SYNDROME; GROWTH RETARDATION; HEART DEATH; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERAMMONEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERNATREMIA; HYPERPROLACTINEMIA; HYPOCALCEMIA; HYPOTENSION; INSOMNIA; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; MENTAL DISEASE; METABOLIC ACIDOSIS; MIOSIS; MYOCARDITIS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PANCYTOPENIA; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; SUICIDAL BEHAVIOR; TACHYCARDIA; TARDIVE DYSKINESIA; TERATOGENICITY; THROMBOCYTOPENIA; TIC; URINE RETENTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 29144505129     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-20051201-10     Document Type: Review

References (51)

1. Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157(1):17-25.
2. Achenbach TM, Howell CT. Are American children's problems getting worse? A 13-year comparison. J Am Acad Child Adolesc Psychiatry. 1993;32(6):1145-1154.
3. Kim WJ; American Academy of Child and Adolescent Psychiatry Task Force on Workforce Needs. Child and adolescent psychiatry workforce: a critical shortage and national challenge. Acad Psychiatry. 2003;27(4):277-282.
4. Freedman R. Schizophrenia. N Engl J Med. 2003;349(18):1738-1749.
5. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol. 2001;39(1):1-14.
6. Dubois D. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Curr Opin Pediatr. 2005;17(2):227-233.
7. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-425.
8. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. 2004;19(6):351-353.
9. Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother. 2001;35(12):1556-1558.
10. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161(9):1709-1711.
11. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2):290-296.
12. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8): 1334-1349.
13. Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother. 1997;31(7-8):867-870.
14. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162-167.
15. Hagg S, Spigset O. Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol. 2001;21(4):382-388.
16. Bryant SM, Zilberstein J, Cumpston KL, Magdziarz DD, Costerisan DD. A case series of ziprasidone overdoses. Vet Hum Toxicol. 2003;45(2):81-82.
17. Buckley NA. Antipsychotic drugs (neuroleptics). In: Dart RC, ed. Medical Toxicology. 3rd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004:861-870.
18. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry. 1996;35(11):1427-1439.
19. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363(9418):1341-1345.
20. Jureidini JN, Doecke CJ, Mansfield PR, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ. 2004;328(7444):879-883.
21. March J, Silva S, Petrycki S, et al.; Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807-820.
22. Vitiello B, Swedo S. Antidepressant medications in children. N Engl J Med. 2004; 350(15):1489-1491.
23. Newman TB. A black-box warning for antidepressants in children? N Engl J Med. 2004;351(16):1595-1598.
24. Public Health Advisory for Adderall and Adderall XR. Food and Drug Administration. February 10, 2005. Available at: http://www. fda.gov/cder/drug/advisory/adderall.htm. Accessed October 31, 2005.
25. National Institute of Mental Health. Antidepressant medications for children and adolescents: information for parents and caregivers. February 8, 2005. Available at: http://www. nimh.nih.gov/healthinformation/antidepres sant_child.cfm. Accessed October 31, 2005.
26. The Use of Medication in Treating Childhood and Adolescent Depression: Information for Physicians. American Psychiatric Association and American Academy of Child and Adolescent Psychiatry. February 1, 2005. Available at: http://www.parentsmedguide.org/physicians medguide.htm. Accessed November 10, 2005.
27. Depressing research. Lancet. 2004;363(9418): 1335.
28. Japsen B. Do these drugs need a warning? The Chicago Tribune. June 9, 2005:1.
29. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391-2399.
30. Adderall. DRUGDEX® System. Greenwood Village, CO: Thomson Micromedex. 2005.
31. Health Canada suspends the market authorization of ADDERALL XR®, a drug prescribed for Attention Deficit Hyperactivity Disorder (ADHD) in children. Health Canada. February 9, 2005. Available at: http://www.hc-sc.gc. ca/english/protection/warnings/2005/2005_ 01.html. Accessed October 31, 2005.
32. Alert for Healthcare Professionals: Adderall and Adderall XR (amphetamine). Food and Drug Administration. February 9, 2005;. Available at: http://www.fda.gov/cder/drug/ InfoSheets/HCP/adderalHCP.htm. Accessed October 31, 2005.
33. Dancea A, Cote A, Rohlicek C, Bernard C, Oligny LL. Cardiac pathology in sudden unexpected infant death. J Pediatr. 2002;141(3):336-342.
34. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90(Suppl 1):i26-29.
35. American Academy of Pediatrics. Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001; 108(4):1033-1044.
36. Kratochvil CJ, Heiligenstein JH, Dittmunn R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784.
37. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002;63(Suppl 12):50-55.
38. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-740.
39. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711.
40. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67(2):149-156.
41. Spiller HA, Lintner CP, Winter ML. Atomoxetine ingestions in children: a report from poison centers. Ann Pharmacother. 2005;39(6):1045-1048.
42. Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry. 2004;161(4):757.
43. Barker MJ, Benitez JG, Ternullo S, Juhl GA. Acute oxcarbazepine and atomoxetine overdose with quetiapine. Vet Hum Toxicol. 2004;46(3):130-132.
44. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol. 2002;40(6):789-801.
45. Litovitz TL, Felberg L, White S, Klein-Schwartz W. 1995 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1996;14(5):487-537.
46. Burns MJ, Palmer BF. Management of Valproic Acid Intoxication. Wellesley, MA: UpToDate; 2005.
47. Gidal BE, Inglese CM, Meyer JF, et al. Diet-and valproate-induced transient hyperammonemia: effect of L-carnitine. Pediatr Neurol. 1997;16(4):301-305.
48. Bryant AE 3rd, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology. 1996;46(2):465-469.
49. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003;9(2):199-216.
50. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia. 1998;39(11):1216-1225.
51. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001;56(1):1405-1409.